Excellent 12-month outcomes of BIOTRONIK’s thin strut bare metal stent with passive PROBIO coating shown in Paris.
BUELACH, Switzerland, May 15, 2012 – BIOTRONIK has announced that the 12-month results of the ENERGY registry were presented at the EuroPCR conference in Paris. ENERGY is a registry in a broad patient population investigating the safety and clinical performance of the PRO-Kinetic Energy bare metal stent system in 1,016 patients. An analysis of each predefined subgroup: patients with acute coronary syndrome (ACS), small vessels, diabetic patients and elderly patients was performed.
The ENERGY study population included a high number of patients with acute coronary syndrome (46%), almost 30% were elderly (≥75 years) patients as well as 39% with highly complex lesions. The 12-month results confirmed the previously presented outcomes with a low MACE rate of only 6.5%. Cardiac death, myocardial infarction and TLR were 0.9%, 1.8% and 3.8% respectively. Even in the acute coronary syndrome (ACS) subgroup which is a more high risk population and thus associated with higher event rates, MACE was only 6.2% at one year.
“Nowadays we are seeing more and more drug eluting stents (DES) being used due to their increased efficacy over bare metal stents (BMS). However, especially for patients with acute coronary syndrome, it is very important to have high performing BMS at hand. PRO-Kinetic Energy is such a high performer with outstanding deliverability and good efficacy that it can be more often used as an alternative to DES,” commented Prof. Raimund Erbel, principal investigator from the West German Heart Center in Essen, Germany.
The PRO-Kinetic Energy is a thin strut (60μm) cobalt chromium bare metal stent, completely sealed with a thin layer of amorphous silicon carbide, PROBIO. This passive coating reduces the interaction between the metal stent and the surrounding tissue which makes the stent more hemocompatible.
About BIOTRONIK SE & Co. KG
As one of the world’s leading cardiovascular medical device companies, with several million implanted devices, BIOTRONIK is represented in over 100 countries with its global workforce of more than 5,600 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face, and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success, and deliver confidence and peace of mind to physicians and their patients worldwide.
More information: www.biotronik.com